Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Bausch Health Companies in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Bausch Health Companies’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 6:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000885590-26-000053
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Expenses | ||
| Cost of goods sold (excluding amortization and impairments of intangible assets) | 721 | 683 |
| Cost of other revenues | 17 | 18 |
| Selling, general and administrative | 861 | 867 |
| Research and development | 163 | 143 |
| Amortization of intangible assets | 241 | 256 |
| Goodwill impairments | 1,426 | — |
| Restructuring, integration and separation costs | 13 | 1 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch Health Companies's SG&A?
- Bausch Health Companies (BHC) reported SG&A of $861M in Q1 2026.
- How has Bausch Health Companies's SG&A changed year-over-year?
- Bausch Health Companies's SG&A decreased by 0.7% year-over-year, from $867M to $861M.
- What is the long-term trend for Bausch Health Companies's SG&A?
- Over 4 years (2021 to 2025), Bausch Health Companies's SG&A has grown at a 7.0% compound annual growth rate (CAGR), from $2.62B to $3.44B.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Bausch Health Companies's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude